Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Personalized Medicine, |
RCV000735379 | SCV000854534 | uncertain significance | Colitis; Inflammation of the large intestine; Hematochezia; Thrombocytopenia | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV000791950 | SCV000931221 | uncertain significance | MHC class II deficiency | 2022-10-24 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 1115 of the CIITA protein (p.Ser1115Asn). This variant is present in population databases (rs138790505, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with CIITA-related conditions. ClinVar contains an entry for this variant (Variation ID: 598994). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV001332302 | SCV001524570 | uncertain significance | Rheumatoid arthritis | 2019-11-08 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Fulgent Genetics, |
RCV002485949 | SCV002787882 | uncertain significance | MHC class II deficiency; Rheumatoid arthritis | 2022-02-24 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV004692214 | SCV005194225 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV000791950 | SCV001462364 | uncertain significance | MHC class II deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |